BirchBioMed is a clinical-stage biomedical company
focused on the clinical evaluation, development and commercialization of anti-scarring drugs,
autoimmune therapeutics and novel strategies for transplantation.

FIRST PATIENT ENROLLED BIRCHBIOMED’S STUDY
INVESTIGATING FS2 FOR THE TREATMENT OF SCARS